COVID-19 severity in asthma patients: a multi-center matched cohort study

  1. Lacey B. Robinson
  2. Liqin Wang
  3. Xiaoqing Fu
  4. Zachary S. Wallace
  5. Aidan A. Long
  6. Yuqing Zhang
  7. Carlos A. Camargo
  8. Kimberly G. Blumenthal

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1080/02770903.2020.1857396
  2. ScreenIT

    SciScore for 10.1101/2020.10.02.20205724: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Institutional Review Board: This study was reviewed by the Partners Human Research Committee and determined to be exempt/non-human subjects research (Protocol 2020P000833).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Statistical analyses were completed using SAS (version 9.4; SAS Institute, Inc.) with a two-tailed P < 0.05 considered statistically significant.
    SAS Institute
    suggested: (Statistical Analysis System, RRID:SCR_008567)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    However, it is possible that we were unable to define all allergic asthma patients due to limitations of case identification by ICD-10-CM codes and anti-allergic medications, many of which are over-the-counter pharmaceuticals. The primary treatment for patients with persistent asthma is inhaled corticosteroids. There is limited evidence regarding the relation between inhaled corticosteroids and COVID-19; however, there is some evidence to suggest therapy may be beneficial.15,26 For example, ciclesonide, an inhaled corticosteroid, has the potential to inhibit viral replication of SARS-CoV-2.27 Moreover, the only therapy with preliminary evidence to support a reduction in mortality in severe COVID-19 is a corticosteroid – dexamethasone.28 A recent rapid meta-analysis attempted to review data on inhaled corticosteroid therapy in SARS, MERS or COVID-19 but found no suitable data for review.29 In light of the potential mechanistic benefit and proven benefits of inhaled corticosteroid therapy in asthma patients, the current recommendations encourage continued use of asthma controller therapy (i.e. inhaled corticosteroids) during the COVID-19 pandemic.16,30 The effect of inhaled corticosteroids on infection with SARS-CoV-2 and the development of COVID-19 is outside the scope of our current study. However, among our asthma cohort, we observed that most asthma patients were prescribed inhaled corticosteroids prior to diagnosis of COVID-19. Future studies aimed at understanding the rel...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.10.02.20205724v1 on medRxiv